Cargando…

A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy

BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PG...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Xu, Zhang, Zhuoli, Guo, Lili, Zhu, Jingjing, Peng, Mingli, Vermorken, Alphonsus J. M., Van de Ven, Wim J. M., Chen, Chao, Cui, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466217/
https://www.ncbi.nlm.nih.gov/pubmed/23056167
http://dx.doi.org/10.1371/journal.pone.0040388
_version_ 1782245650331598848
author Chao, Xu
Zhang, Zhuoli
Guo, Lili
Zhu, Jingjing
Peng, Mingli
Vermorken, Alphonsus J. M.
Van de Ven, Wim J. M.
Chen, Chao
Cui, Yali
author_facet Chao, Xu
Zhang, Zhuoli
Guo, Lili
Zhu, Jingjing
Peng, Mingli
Vermorken, Alphonsus J. M.
Van de Ven, Wim J. M.
Chen, Chao
Cui, Yali
author_sort Chao, Xu
collection PubMed
description BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. METHODS: First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). RESULTS: The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). CONCLUSION: This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future.
format Online
Article
Text
id pubmed-3466217
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34662172012-10-10 A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy Chao, Xu Zhang, Zhuoli Guo, Lili Zhu, Jingjing Peng, Mingli Vermorken, Alphonsus J. M. Van de Ven, Wim J. M. Chen, Chao Cui, Yali PLoS One Research Article BACKGROUND: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. METHODS: First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). RESULTS: The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). CONCLUSION: This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future. Public Library of Science 2012-10-08 /pmc/articles/PMC3466217/ /pubmed/23056167 http://dx.doi.org/10.1371/journal.pone.0040388 Text en © 2012 Chao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chao, Xu
Zhang, Zhuoli
Guo, Lili
Zhu, Jingjing
Peng, Mingli
Vermorken, Alphonsus J. M.
Van de Ven, Wim J. M.
Chen, Chao
Cui, Yali
A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
title A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
title_full A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
title_fullStr A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
title_full_unstemmed A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
title_short A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy
title_sort novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466217/
https://www.ncbi.nlm.nih.gov/pubmed/23056167
http://dx.doi.org/10.1371/journal.pone.0040388
work_keys_str_mv AT chaoxu anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT zhangzhuoli anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT guolili anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT zhujingjing anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT pengmingli anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT vermorkenalphonsusjm anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT vandevenwimjm anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT chenchao anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT cuiyali anovelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT chaoxu novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT zhangzhuoli novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT guolili novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT zhujingjing novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT pengmingli novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT vermorkenalphonsusjm novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT vandevenwimjm novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT chenchao novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy
AT cuiyali novelmagneticnanoparticledrugcarrierforenhancedcancerchemotherapy